Literature DB >> 1629952

Deletion analysis of two tandemly arranged virulence genes in myxoma virus, M11L and myxoma growth factor.

A Opgenorth1, K Graham, N Nation, D Strayer, G McFadden.   

Abstract

Myxoma virus (MYX) is a leporipoxvirus of rabbits that induces a lethal syndrome characterized by disseminated tumorlike lesions, generalized immunosuppression, and secondary gram-negative bacterial infection. A MYX deletion mutant (vMYX-GF- delta M11L) was constructed to remove the entire myxoma growth factor (MGF) coding sequence and that for the C-terminal five amino acids of the partially overlapping upstream gene, M11L. Unexpectedly, this deletion completely abrogates the capacity of MYX to cause the characteristic disease symptoms of myxomatosis. Upon inoculation of rabbits with vMYX-GF- delta M11L, recipient animals developed only a benign, localized nodule reminiscent of a Shope fibroma virus-induced tumor in which a single primary lesion appeared at the site of injection and then completely regressed within 14 days, leaving the animals resistant to challenge with wild-type MYX. No evidence of the purulent conjunctivitis and rhinitis that always accompany wild-type MYX infection was observed. To ascertain whether the attenuation observed in vMYX-GF- delta M11L was due to a combined effect of the MGF deletion and alteration of the upstream M11L gene, two additional MYX recombinants were constructed: an MGF- virus (vMYX-GF-) containing an intact M11L gene and an M11L- virus (vMYX-M11L-) containing an intact MGF gene. Infection with vMYX-GF- resulted in moderated symptoms of myxomatosis, but all clinical stages of the disease were still detectable. In contrast, disruption of M11L alone dramatically reduced the virus virulence, resulting in a nonlethal syndrome whose clinical course was nevertheless distinct from that of vMYX-GF- delta M11L. Upon inoculation with vMYX-M11L-, rabbits developed primary and secondary tumors which were larger and more circumscribed than those of wild-type MYX recipients. Whereas wild-type MYX infection always includes severe, purulent conjunctivitis and rhinitis, vMYX-M11L- recipients remained healthy and displayed only minimal signs of respiratory distress. By about 30 days after infection, the tumors induced by vMYX-M11L- had completely regressed and these animals were immune to challenge with wild-type MYX. Histological analysis indicated that tumors induced by vMYX-M11L- are much more heavily infiltrated with macrophages and heterophils and that the sites of viral replication are more edematous and necrotic than those of wild-type infection, suggesting that the host was able to mount a more vigorous inflammatory response to vMYX-M11L- infection.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1629952      PMCID: PMC241298     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  A short description of the poxvirus group (vaccinia and related viruses).

Authors:  F FENNER; F M BURNET
Journal:  Virology       Date:  1957-10       Impact factor: 3.616

Review 2.  Transforming growth factor-alpha: an oncodevelopmental growth factor.

Authors:  D S Salomon; N Kim; T Saeki; F Ciardiello
Journal:  Cancer Cells       Date:  1990-12

Review 3.  Poxviruses: an emerging portrait of biological strategy.

Authors:  P Traktman
Journal:  Cell       Date:  1990-08-24       Impact factor: 41.582

Review 4.  Epidermal growth factor.

Authors:  G Carpenter; S Cohen
Journal:  J Biol Chem       Date:  1990-05-15       Impact factor: 5.157

5.  Synthesis and structure-activity study of myxoma virus growth factor.

Authors:  Y Z Lin; X H Ke; J P Tam
Journal:  Biochemistry       Date:  1991-04-02       Impact factor: 3.162

6.  Identification and DNA sequence of the Shope fibroma virus DNA topoisomerase gene.

Authors:  C Upton; A Opgenorth; P Traktman; G McFadden
Journal:  Virology       Date:  1990-06       Impact factor: 3.616

7.  Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence.

Authors:  C Upton; J L Macen; M Schreiber; G McFadden
Journal:  Virology       Date:  1991-09       Impact factor: 3.616

Review 8.  Poxvirus pathogenesis.

Authors:  R M Buller; G J Palumbo
Journal:  Microbiol Rev       Date:  1991-03

9.  Deletion of the growth factor gene related to EGF and TGF alpha reduces virulence of malignant rabbit fibroma virus.

Authors:  A Opgenorth; D Strayer; C Upton; G McFadden
Journal:  Virology       Date:  1992-01       Impact factor: 3.616

10.  A comparison of the virulence for European rabbits (Oryctolagus cuniculus) of strains of myxoma virus recovered in the field in Australia, Europe and America.

Authors:  F FENNER; I D MARSHALL
Journal:  J Hyg (Lond)       Date:  1957-06
View more
  52 in total

1.  Myxoma and vaccinia viruses exploit different mechanisms to enter and infect human cancer cells.

Authors:  Nancy Y Villa; Eric Bartee; Mohamed R Mohamed; Masmudur M Rahman; John W Barrett; Grant McFadden
Journal:  Virology       Date:  2010-03-24       Impact factor: 3.616

2.  The vaccinia virus F1L protein interacts with the proapoptotic protein Bak and inhibits Bak activation.

Authors:  Shawn T Wasilenko; Logan Banadyga; David Bond; Michele Barry
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

3.  Structure of M11L: A myxoma virus structural homolog of the apoptosis inhibitor, Bcl-2.

Authors:  Andrew E Douglas; Kevin D Corbett; James M Berger; Grant McFadden; Tracy M Handel
Journal:  Protein Sci       Date:  2007-04       Impact factor: 6.725

4.  Current Status for High Titre Poxvirus Stock Preparation in CEF Under Serum-Free Medium Conditions: Implication for Vaccine Development.

Authors:  Philippe-Alexandre Gilbert; Lacrimioara Comanita; John Barrett; Andrew Peters; Marta Szabat; Grant McFadden; Gregory A Dekaban
Journal:  Cytotechnology       Date:  2005-06       Impact factor: 2.058

5.  Myxoma virus M11L blocks apoptosis through inhibition of conformational activation of Bax at the mitochondria.

Authors:  Jin Su; Gen Wang; John W Barrett; Timothy S Irvine; Xiujuan Gao; Grant McFadden
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

6.  Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo.

Authors:  Marianne M Stanford; Mae Shaban; John W Barrett; Steven J Werden; Philippe-Alexandre Gilbert; Joe Bondy-Denomy; Lisa Mackenzie; Kevin C Graham; Ann F Chambers; Grant McFadden
Journal:  Mol Ther       Date:  2007-11-13       Impact factor: 11.454

7.  Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin.

Authors:  Xue Qing Lun; Hongyuan Zhou; Tommy Alain; Beichen Sun; Limei Wang; John W Barrett; Marianne M Stanford; Grant McFadden; John Bell; Donna L Senger; Peter A Forsyth
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

8.  Induction of alpha/beta interferon by myxoma virus is selectively abrogated when primary mouse embryo fibroblasts become immortalized.

Authors:  Fuan Wang; John W Barrett; Yiyue Ma; Gregory A Dekaban; Grant McFadden
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

9.  The myxoma virus m-t5 ankyrin repeat host range protein is a novel adaptor that coordinately links the cellular signaling pathways mediated by Akt and Skp1 in virus-infected cells.

Authors:  Steven J Werden; Jerry Lanchbury; Donna Shattuck; Chris Neff; Max Dufford; Grant McFadden
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

10.  Myxoma virus encodes an alpha2,3-sialyltransferase that enhances virulence.

Authors:  R J Jackson; D F Hall; P J Kerr
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.